Metrics as of 10/17/2026, 02:50 AM (Berlin time), refresh in progress.
Medpace Holdings Stock
Medpace Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- August James Troendle
- Employees
- 6,500
- Market cap
- $17.3 B
- IPO
- 11/08/2016
Medpace Holdings, Inc., headquartered in Cincinnati, USA, operates as a contract research organization within the Healthcare sector. Founded in 1992, the company provides clinical development and research services to clients in the pharmaceutical, biotechnology, and medical device industries. Its operational reach…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Medpace Holdings stock: price history
1D
-1.6%
1W
+1.0%
1M
+0.3%
6M
+18.8%
YTD
+10.1%
1Y
+18.7%
2Y
+78.5%
5Y
+230.6%
10Y
+2,018.0%
Next earnings date
Next earnings date
21/10/2026 (in 4 days)
Volatility around earnings
~154% stronger price swings than usual
Medpace Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Medpace Holdings, Inc. operates as a Contract Research Organization (CRO) and provides comprehensive clinical development services for the pharmaceutical, biotechnology, and medical device sectors. The service portfolio covers the entire product lifecycle, starting with Phase I studies through to post-market surveillance in Phase IV. Core services include development program design, coordination of central laboratory services, project management, regulatory support, and data management and pharmacovigilance. The company demonstrates strong specialization in the areas of oncology and metabolic diseases.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about Medpace Holdings
Analyst assessment of Medpace Holdings
PRICE TARGET LOW
US$515.00
CONSENSUS
US$620.44
MEDIAN
US$624.00
PRICE TARGET HIGH
US$700.00
0
STRONG BUY
4
BUY
15
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Hold
As of: 07/10/2026
Medpace Holdings stock metrics
P/E
35.56
P/B
40.35
EV/EBITDA
27.44
RETURN ON EQUITY
28.0%
NET MARGIN
17.2%
DEBT/EQUITY
0.33
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.2%
FLOAT SHARES
22,657,565
AVG. DAILY VOLUME (30D)
249,434
Insider transactions (SEC)
BURWIG SUSAN E
BURWIG SUSAN E
McCarthy Cornelius P. III
Carley Brian T
Kraft Robert O.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Medpace Holdings stock
What does Medpace Holdings do?
Medpace Holdings, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is August James Troendle, the company employs around 6,500 people.
The IPO was on 11/08/2016; the stock trades on NASDAQ under the ticker MEDP.
What do analysts say about Medpace Holdings stock?
19 analysts rate the stock, the consensus is Hold (as of 07/10/2026).
The average price target is US$620.44, ranging from US$515.00 to US$700.00, with a median of US$624.00.
This is an external assessment, not a statement by Market Jury.
When does Medpace Holdings report next?
The next earnings date is 21/10/2026.
Around past earnings, price swings were roughly 154% stronger than usual.
Does Medpace Holdings pay a dividend?
No, Medpace Holdings currently does not pay a dividend.
Which stocks are comparable to Medpace Holdings?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Medpace Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Medpace Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.